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Neonatal infections caused by GBS and Escherichia coli K1
still have unacceptably high mortality and morbidity rates (6) . To supplement current antibiotic therapy, we have developed human MAb with immunotherapeutic potential. Human IgM MAb produced against the group carbohydrate of GBS or the E. coli K1 capsule were found to protect against lethal infections in animal models (7, 8) . Although administration of human MAb does not have obvious risks, it is still necessary to insure the safety of individual MAb and the methods used for their preparation. Moreover, because these MAb are intended for treatment of infections in neonates, exploring their safety is of paramount importance.
Before initiating formal preclinical safety and PK studies, we performed a preliminary study using two nonhuman primate neonates. The data indicate the GBS MAb is safe without apparent toxicity for the major organ systems or impairment of bone marrow function. Further, in neonatal monkeys the IgM MAb has a half-life of approximately 2.5 d and maintains commensurate opsonic activity.
MATERIALS AND METHODS
Animals. Less than 7-d-old male and female monkeys (M. fascicularis) were obtained from and were housed by the Regional Primate Research Center at the University of Washington, Seattle. The animals were housed in individual isolettes in a room designated for newborn monkeys and separated from all other animals. One male (T89001) weighing 550 g and one female monkey (T89008) weighing 416 g were administered antibody at 5 d of age. These particular animals had been rejected bv their mothers and were therefore bottle fed before and throughout the study. The Primate Center conforms to the Passive immunotherapy with MAb may provide a superior National Institutes of Health Guide for the Care and Use of alternative or adjunctive treatment modality to standard antibi-Laboratory Animals. otic treatment of bacterial infections. Although several murine Human MAb. A human IgM MAb (4B9) against the group B antitumor MAb have been administered to humans (I), only polysaccharide of GBS was derived by Epstein Barr virus transone human and one murine MAb, both against the core region formation of normal B cells (9) . Antibody was purified from of gram-negative bacterial endotoxin, have been similarly tested nutrient-exhausted culture supernatant by affinity chromatogra- (2) . Despite the recent development and clinical testing of mouse phy on a murine antihuman IgM column (7) . Concentrated MAb, it is apparent that human MAb offer particular advantages culture supernatant was passed over a Sepharose 4B-murine (3), and may be preferred. For example, human MAb should MAb (Genetic Systems Corp., Seattle, WA) antihuman IgM elicit, at most, a minimal host response and possess extended column (CNBr-activated Sepharose). Bound antibody was eluted half-lifes. Before MAb of any origin can be considered for clinical with 2 M MgClz in PBS. Purified antibody preparations were use, their safety must be established. The likelihood that human dialyzed against 10 mM phosphate in physiologic saline, filter MAb will be safe is supported by extensive clinical experience sterilized, and assayed for pyrogen using the Limulus Amebocyte with i.v. administered human Ig-based formulations. In adults assay QCL-100 (M. A. Bioproducts, Walkersville, MD). Purity and neonates, these products have not elicited significant nega-was examined by SDS-PAGE of reduced samples followed by tive side effects and therefore appear safe for general use (4, 5) .
silver nitrate staining (10, 1 1). Antibody activity and integrity PK assay. A PK assay was developed using a MAb anti-Id ELISA-based capture format. An antihuman MAb 4B9 idiotypespecific murine MAb was produced by fusing spleen cells from Balb/C mice immunized with the human MAb to murine myeloma cells (P3X63Ag8, 12). The anti-Id used in the PK assays reacted only with the immunizing IgM antibody, and not other human IgM MAb or the IgM fraction of pooled normal human serum (ICN ImmunoBiologicals, Lisle, IL), suggesting that this anti-Id did not detect a cross-reactive idiotypic determinant present in other human antibodies. The multivalency of the IgM MAb was exploited by using one anti-Id MAb as both the plasticbound capture antibody and the fluid-phase biotinylated signal source. For the assay, microtiter plate wells were coated overnight at 4°C with 100 pL of anti-Id (8F2, IgG2,) at 2.0 pg/mL in carbonate-bicarbonate buffer. After washing and blocking (5% nonfat dry milk solution in 0.02% Tween/PBS) diluted control and serum samples were added to the wells followed by incubation at room temperature for 60 min. After an additional wash step, microtiter wells received biotinylated anti-Id (100 pL/well) for 45 min at room temperature, were washed, and were treated with Vectastain (Vector Labs, Burlingame, CA) for an additional 20 min (1 3). After washing and substrate addition, the assay was completed as previously described. Antibody half-life was calculated from the PK assay data using a computer software program (PKCALC, 14) .
Opsonophagocyfic assay. The functional activity or "pharmacodynamics" of the antibody in serum samples was quantitated following a protocol described previously (8) . MAb-mediated opsonic activity in monkey T89008 serum samples was assayed against two GBS (capsule serotype 111) clinical isolates (COH 1 and type IIIR, provided by Drs. C. Rubens and H. Hill, University of Utah School of Medicine, Salt Lake City, UT, respectively, (15, 16) . Serum samples were diluted 1:1000 in PBS to dilute out opsonic activity detected in prebleed sample. For the assay, duplicate tubes were prepared containing in 500 pL 250 pL of diluted serum or MAb, 50 pL of freshly isolated human neutrophils (5 x 107/mL), 75 pL human serum as a complement source, 100 pL of the GBS strains (4 x 102 CFU/mL), and 25 pL of Hanks' Balanced salt solution containing 10 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonc acid and 0.1 % gelatin. The bacteria were first incubated with antibody or serum for 30 min at 37"C, followed by the addition of the other assay components. The entire mixture was rotated for 60 min at 37°C. Negative controls were prebleed serum samples for postinjection serum samples and reaction mixtures lacking complement (heatinactivated FCS substituted for complement) for MAb experiments. In other experiments (data not shown), substituting a negative control human MAb, omitting the neutrophils, or omitting the complement all gave very similar negative control values. Therefore, in these experiments, only the complement control was used. ples)/(CFU remaining after incubation with neutrophils, complement, and prebleed serum)] or 100 x [I-(CFU remaining after incubation with neutrophils, complement, and MAb)/(CFU remaining after incubation with neutrophils, FCS, and MAb)].
RESULTS
PK. Affinity column purified antibody was shown by SDS-PAGE to be essentially free of protein contaminants (data not shown) and to contain 0.26 ng endotoxin/8.5 mg MAb (30 pg/ mg). Five-d-old cynomolgous (M. fascicularis) monkeys were injected i.v. with either 17.8 (T89001) or 230 mg/kg (T89008) of MAb 4B9. Blood samples were drawn starting 5 min after infusion for 30 d. The MAb concentration in serum was quantitated using an anti-Id-based capture ELISA. Because IgM antibodies are multivalent, it was found that the same murine antiId MAb could function as both the capture antibody and the signal antibody (biotinylated). By limiting the capture antibody, the idiotopes on each 4B9 IgM molecule were not saturated, thereby allowing signal anti-Id MAb to bind the same IgM molecules. The assay is sensitive to 1 ng MAb/mL and is not affected by 4 0 % monkey or human serum.
Using this assay, it appeared that in high and low dose monkeys (Fig. 2) . Opsonic activity. Although the physical presence of antibody was detected in serum by the PK assay, an equally important question is whether the antibody retains opsonic or functional activity during this time. Antibody opsonic activity was quantitated in the serum samples obtained from monkey T89008. Serum from each time point was diluted 1:1000 and used in opsonic assays against two serotype 111 GBS clinical isolates (COH 1 and type IIIR). The data show that the pharmacodynamics of the MAb differ depending on the clinical isolate (Fig.  3) . Strain COH 1 appears to require less antibody to be effectively opsonized than does strain type IIIR. This observation is reflected in control opsonization experiments when the same antibody administered to the monkeys was tested against these strains (Fig.  4) . Approximately four times more MAb was necessary to provide 50% of the maximal opsonic activity (80% killing) against strain type IIIR than was required against strain COH 1 (80 versus 20 ng/mL, respectively). Because the relative opsonic activity of control and in vivo circulating MAb was the same, these data suggest that the physical detection of the MAb (PK) is reflected by its functional opsonic activity.
Safety parameters. The safety of the MAb was assessed by observing clinical signs after injection and by monitoring a number of clinical chemistry and hematology parameters. During and after MAb administration the monkeys did not demonstrate any behavioral changes that would suggest discomfort, pain, or trauma. Their general activity and feeding levels remained unchanged throughout the study. Blood samples for these studies were obtained before injection and then at approximately 7-or 15-d intervals. Values for kidney function (creatinine and blood urea nitrogen) and liver enzymes (serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase) were within normal limits throughout the study, except for the prebleed and 7-d bleed for monkey T89001, which had slightly elevated SGOT levels due to hemolysis of the sample (Table 1) . Extensive evaluation of hematology parameters also shows that there was little fluctuation from the prebleed values, suggesting the MAb did not adversely affect circulating cells or bone marrow function ( 
DISCUSSION
These studies report the first safety and half-life data in which neonatal monkeys were administered a human IgM MAb. Two 5-d-old cynomolgous (M. fascicularis) monkeys were infused with either 17.8 or 230 mg/kg of an anti-GBS HuMAb. Both doses were well tolerated based on clinical observation and safety parameters. No apparent changes from prebleed values occurred in serum levels of liver transaminases, in serum creatinine clearance by the kidneys, or in hematologic parameters. The circulating half-life of the MAb was directly quantified using an anti-Id capture ELISA was found to be approximately 2.5 d regardless of the antibody dosage. The integrity and activity of antibody Fc regions was not determined by the anti-Id assay. To explore whether the IgM MAb retained functional activity, the same monkey serum samples were tested for opsonic activity in an in vitro assay. Our results show that after 30 d of in vivo circulation the antibody still maintains opsonic activity. Moreover, in control experiments comparing the same MAb administered to the monkeys with MAb in the serum samples, it was shown that they both had similar relative activities against the two GBS clinical isolates, further suggesting the antibody was stable after long-term in vivo passage.
One particular focus of these studies was the half-life of an IgM MAb in neonatal monkeys. At birth there is little or no IgM present in the neonate because IgM antibodies are not transplacentally passed to the fetus. Therefore, the only data on the half-life of human IgM antibodies are from studies in juveniles and adults, indicating that the average half-life of IgM antibodies is approximately 5 d (1 7). The finding that the GBS MAb has a half-life of approximately 2.5 d in cynomolgous monkeys is encouraging, and leads us to anticipate that the half-life will be no less in human neonates. A 2-to 3-d half-life should avoid the need for a particularly high antibody dosage to maintain a clinically efficacious concentration of circulating antibody.
The half-life directly relates to predicting the dosage necessary to manifest clinical efficacy. An average anticipated dosage of 20 mg/kg in human neonates is based on body weight extrapolations from studies in a neonatal rat infection model (8) . This dosage was administered to monkey T8900 1 (1 7.8 mg/kg) and approximately 10 times this amount to monkey T89008 (230 mg/kg). Based on data obtained from opsonophagocytic experiments performed with serum from the high-dose monkey and MAb from the same lot, it seems likely that even in the monkey receiving 17.8 mg/kg, an adequate concentration of MAb remained after 25 d to opsonize even the more resistant GBS strain (type IIIR).
Because human MAb have not previously been administered to neonatal monkeys or humans, the only relevant safety studies are with i.v. Ig products intended for use in preventing and/or treating neonatal bacterial infections. Studies in human neonates have shown that doses up to 750 mg/kg are safe in this patient population, and preliminary studies indicate that these products may possess antiinfective potential (5, 18) . The safety in neonates of a formulation containing 12% IgM Ig by weight has also been shown (19) . However, the use of i.v. Ig formulations may not be without its risks. T o maintain elevated serum levels of anti-GBS antibodies, administration of 500 mg/kg i.v. Ig was required (5) .
At this dosage, the possibility arises of increasing the catabolic rate of IgG and perhaps reducing IgG titers of specific opsonic antibodies (20). In addition, in experimental GBS infection studies, high doses of i.v. Ig administered alone (21) or in conjunction with antibiotics resulted in less therapeutic efficacy compared with control treatments (22). These studies suggest that high doses of i.v. Ig may cause phagocytic cell receptor blockade or other immunoinhibitory activity. By using substantially smaller doses of human MAb, we hope to avoid these potential problems and gain the advantage of administering standardized dosages of opsonic antibodies.
We began this effort by administering one human IgM MAb to healthy, neonatal nonhuman primates. The apparent safety of this human IgM in neonatal monkeys encouraged us to proceed with developing the anti-GBS MAb for additional preclinical safety and PK studies.
